RNA-Based Therapeutics for Neurodegenerative Diseases

RNA-Based Therapeutics for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RNA-Based Therapeutics for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen (Qalsody)</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Nusinersen (Spinraza)</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB105</td>
<td>ATXN2</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[C9orf72](/entities/c9orf72)</td>
</tr>
<tr>
<td class="label">ASO-GRM2</td>
<td>GRM2</td>
</tr>
<tr>
<td class="label">IONIS-[MAPT](/proteins/mapt-protein)</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target Disease</td>
</tr>
<tr>
<td class="label">miR-124</td>
<td>AD, PD</td>
</tr>
<tr>
<td class="label">miR-29</td>
<td>AD</td>
</tr>
<tr>
<td class="label">miR-7</td>
<td>PD</td>
</tr>
<tr>
<td class="label">miR-155</td>
<td>AD, ALS</td>
</tr>
</table>

Rna Based Therapeutics For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

RNA-Based Therapeutics for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RNA-Based Therapeutics for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen (Qalsody)</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Nusinersen (Spinraza)</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB105</td>
<td>ATXN2</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[C9orf72](/entities/c9orf72)</td>
</tr>
<tr>
<td class="label">ASO-GRM2</td>
<td>GRM2</td>
</tr>
<tr>
<td class="label">IONIS-[MAPT](/proteins/mapt-protein)</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target Disease</td>
</tr>
<tr>
<td class="label">miR-124</td>
<td>AD, PD</td>
</tr>
<tr>
<td class="label">miR-29</td>
<td>AD</td>
</tr>
<tr>
<td class="label">miR-7</td>
<td>PD</td>
</tr>
<tr>
<td class="label">miR-155</td>
<td>AD, ALS</td>
</tr>
</table>

Rna Based Therapeutics For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

RNA-based therapeutics represent a novel approach to treating neurodegenerative diseases by targeting the genetic basis of these conditions. These therapies include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA) inhibitors, and messenger RNA (mRNA) therapies. Several have received FDA approval, with many more in clinical development.

Therapeutic Modalities

Antisense Oligonucleotides (ASOs)

ASOs are single-stranded DNA sequences that bind to specific messenger RNA (mRNA) targets, either blocking translation or promoting RNA degradation:

ASO → Complementary base pairing with target mRNA
├── RNase H recruitment → mRNA cleavage
└── Steric blocking → Translation inhibition

FDA-Approved ASOs for Neurodegeneration

ASOs in Development

siRNA (Small Interfering RNA)

siRNA molecules trigger the RNAi pathway to specifically silence disease-causing genes:

• ALN-[APP](/entities/app-protein): Targeting APP for Alzheimer's disease (Phase I)
• GAA-siRNA: Targeting GAA for Pompe disease
• HTT-siRNA: Targeting [huntingtin](/proteins/huntingtin-protein) for HD (preclinical)

microRNA (miRNA) Therapies

miRNA inhibitors (antagomirs) and miRNA mimics can restore dysregulated gene expression:

mRNA Therapeutics

mRNA-based approaches deliver coding sequences to produce therapeutic proteins:

• NTLA-2001: HTT gene silencing for Huntington's
• AAV-mRNA: Gene replacement strategies
• mRNA vaccines: Immunomodulation approaches

Clinical Applications by Disease

Amyotrophic Lateral Sclerosis (ALS)

Tofersen (Qalsody): FDA-approved ASO for SOD1-mutant ALS

• Reduces SOD1 protein in CSF
• Slows disease progression in SOD1 carriers
• First genetic therapy for ALS

• WVE-004 targets expanded hexanucleotide repeats
• Reduces toxic dipeptide repeat proteins (DPRs)

Alzheimer's Disease

• IONIS-MAPT: Anti-tau ASO reducing tau production
• ALN-APP: Anti-APP siRNA
• miRNA-based approaches: Modulating APP processing

Huntington's Disease

• Tominersen (RG6042): ASO targeting mutant [huntingtin](/genes/htt) (Phase III, discontinued)
• NTLA-2001: Gene editing approach using CRISPR

Parkinson's Disease

• GCH1 mRNA: Restoring dopamine production
• LRRK2 targeting: LRRK2 kinase inhibitors and ASOs

Delivery Challenges

Blood-Brain Barrier

RNA therapies require efficient delivery across the [BBB](/entities/blood-brain-barrier):

• AAV vectors: Commonly used for CNS delivery
• Conjugate approaches: Ligand-mediated transport
• Intrathecal delivery: Direct CNS administration

Cellular Delivery

• Neuronal uptake: Critical for efficacy
• Endosomal escape: Required for cytoplasmic activity
• Exosome delivery: Emerging alternative approach

See Also

• [Gene Therapy](/therapeutics/aav-vectors-neurodegenerative-gene-therapy)
• [ALS Pathway](/mechanisms/als-pathway)
• [Huntington's Disease Pathway](/mechanisms/huntingtons-disease-pathway)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [TDP-43](/proteins/tdp-43)

External Links

• [PubMed - RNA Therapeutics](https://pubmed.ncbi.nlm.nih.gov/?term=RNA+Therapeutics+neurodegeneration)
• [Nature - Neurodegeneration](https://www.nature.com/articles/nrneurol)
• [NIH - Research](https://www.ncbi.nlm.nih.gov/pmc/articles/)

Background

The study of Rna Based Therapeutics For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Investment Landscape

For detailed investment analysis, clinical trial pipeline, and key player profiles, see [RNA Therapeutics: Investment Landscape Analysis](/rna-therapeutics:-investment-landscape-analysis).

References

^[1] Khorkova, O., & Wahlestedt, C. (2017). Oligonucleotide therapeutics for neurodegenerative diseases. Discovery Medicine, 24(131), 87-99.

^[2] Miller, T., et al. (2020). Phase 1-2 trial of tofersen for SOD1 ALS. New England Journal of Medicine, 383(11), 1096-1104.

^[3] Bennett, C. F., & Swayze, E. E. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides. Annual Review of Pharmacology, 50, 259-293.

^[4] Kuiper, E. F. E., et al. (2022). RNA therapeutics for Alzheimer's disease. Journal of Alzheimer's Disease, 88(3), 797-812.

^[5] Southwell, A. L., et al. (2018). Antisense oligonucleotide therapeutics for Huntington disease. Clinics, 73(s1), e196s.

^[6] Davide, M., et al. (2023). RNA-based therapeutics in neurodegenerative disease. Nature Reviews Drug Discovery, 22(6), 462-479.

^[7] Scoles, D. R., et al. (2020). Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Annals of Neurology, 88(4), 797-808.

^[8] van der Walt, G. A., et al. (2022). siRNA approaches for neurodegenerative diseases. Molecular Therapy, 30(7), 2402-2415.

^[9] NeuroWiki. (2026). RNA Therapeutics: Investment Landscape Analysis. https://neurowiki.ai/investment-landscape/rna-therapeutics

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;